公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 毕得医药(688073) 唐爱金 医药首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业分析师 执业编号：S1500524120003 邮 箱：hexin1@cindasc.com 证券研究报告 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 业绩呈现边际加速趋势，经营效率显著提升 [Table_ReportDate] 2025 年 08 月 24 日 [Table_S 事件：2025 ummar年y]8 月 21 日，公司发布《2025 年半年度报告》。2025H1 公司 实现营业收入 6.28 亿元，同比增长 17.91%；实现归母净利润 0.73 亿元， 同比增长 41.60%；实现扣除股份支付影响后的净利润 0.90 亿元，同比增长 70.60%。单季度来看，2025Q2 公司实现营业收入 3.31 亿元，同比增 ...

Investment Rating - The report assigns a "Buy" rating for the stock of the company, indicating a strong performance relative to the benchmark index [14]. Core Insights - The company's revenue for H1 2025 reached 920 million yuan, a year-on-year increase of 23.48%, while the net profit attributable to the parent company was 72 million yuan, a decline of 26.54% [1]. - The overall gross margin for H1 2025 was 31.05%, down 9.82 percentage points year-on-year, primarily due to downward pressure on order prices and depreciation from new capacity [2]. - The CDMO (Contract Development and Manufacturing Organization) business showed significant growth, with revenue increasing by 60.92% year-on-year to 548 million yuan in H1 2025 [3]. - Domestic demand is beginning to recover, with revenue from Chinese clients growing by 25.00% to 261 million yuan in H1 2025 [4][5]. - The company is strategically expanding into high-growth areas such as targeted protein degradation drugs, peptides, and ADC (Antibody-Drug Conjugates) [6]. Financial Summary - The company is projected to achieve total revenue of 1.987 billion yuan in 2025, with a year-on-year growth rate of 17.6% [7]. - The estimated net profit attributable to the parent company for 2025 is 177 million yuan, reflecting a year-on-year decline of 19.5% [8]. - The gross margin is expected to be 33.4% in 2025, down from 42.5% in 2023 [7].

Core Viewpoint - The company is enhancing its strategic focus on major clients by establishing a dedicated service team to improve customer response efficiency and satisfaction, while expanding its collaboration with multinational corporations (MNCs) across the entire drug development cycle [1] Group 1: Strategic Initiatives - The company has initiated a major client strategy since last year, forming a "triangular" business team consisting of client managers, solution managers, and delivery managers to provide in-depth services to strategic clients [1] - A specialized major client service team has been established this year to coordinate business development resources across regions including China, the US, and Europe, significantly improving customer response efficiency and satisfaction [1] Group 2: Collaboration with MNCs - The collaboration with MNCs has evolved from supplying molecular building blocks to a comprehensive CMC (Chemistry, Manufacturing, and Controls) service, with increasing depth and project scale [1] - The company now covers the entire R&D cycle for MNCs, including drug discovery, clinical development, and CMC services from clinical phases I-III to commercialization [1] Group 3: Innovation and Project Development - The company is leveraging its solid foundation of cooperation and client trust to enter the new molecular pipeline development field for MNCs, with ongoing projects in cutting-edge areas such as peptides (non-natural amino acid building blocks) and ADC (antibody-drug conjugates) design [1] - The company is continuously deepening its collaborative efforts in innovative therapies [1]

Group 1 - The company has systematically laid out AI applications across multiple business areas, including the development of over 80 million novel molecular building blocks to address structural optimization challenges in new drug design [1] - In the CDMO process development area, the company has enhanced collaboration between its process development and digital teams, utilizing high-density data generated from automation to build machine learning models that optimize R&D processes [1] - The company achieved a revenue of 920 million yuan in the first half of the year, representing a year-on-year growth of 23.48%, with a strategic focus on revenue scale expansion and resource allocation towards technology services and CMC business [1] Group 2 - The company reported a net cash flow from operating activities of 467 million yuan in the first half of the year, a significant increase of 240.62% compared to the same period last year, with new CDMO orders growing by 19.88% [2] - Revenue from multinational pharmaceutical companies (MNCs) increased by 69.73% year-on-year, indicating deeper collaboration with these strategic clients [2] - The company’s mature workshop maintains a capacity utilization rate of 60%-70%, while a newly launched workshop is in the ramp-up phase, expected to gradually release capacity as new projects are introduced [2] Group 3 - The molecular building block market exhibits a dual structure, with significant price pressure in the generic product sector due to high competition, while high-value products maintain relatively stable prices [3] - The company aims to enhance product design to improve molecular rationality and ensure solution effectiveness through demand-driven approaches [3] - The company is focused on improving its digital sales system and global supply chain responsiveness, as well as integrating molecular building block resources with external cheminformatics platforms to strengthen customer engagement [3]

Summary of the Conference Call for Yaoshi Technology Company Overview - **Company**: Yaoshi Technology - **Industry**: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Key Financial Metrics - **Revenue**: 920 million CNY, up 23.48% year-on-year [2][4] - **Net Profit**: 72.5 million CNY, down 26.54% year-on-year [2][4] - **Net Profit Excluding Non-recurring Items**: 59.6 million CNY, down 11.82% year-on-year [2][4] - **Operating Cash Flow**: 467 million CNY, up 240.62% year-on-year [2][4] - **Contract Liabilities**: 114 million CNY, up 103.27% year-on-year [2][4] - **Gross Margin**: Downward trend but Q2 showed a slight increase of 1.4 percentage points from Q1, stabilizing around 35%-45% [2][4][8] Business Performance and Strategy - **CDMO New Orders**: Increased by 19.88%, with large multinational pharmaceutical companies contributing 367 million CNY, up 69.73% [2][4] - **Clinical Projects**: Over 1,100 early clinical to Phase II projects and 53 Phase III and commercialization projects completed [2][4][16] - **Focus Areas**: Emphasis on quality and innovation, strategic customer focus, and enhancing service capabilities [3][6][28] - **New Business Development**: Rapid growth in new chemical entities such as peptides, ADC (Antibody-Drug Conjugates), and TPD (Targeted Protein Degradation) [3][18] Market Dynamics - **Price Competition**: Intense price competition in both domestic and international markets, with strategies to sacrifice some margins for order acquisition [10][11] - **Market Segmentation**: Revenue from large multinational clients increased to 40% of total revenue, with significant growth in European and Japanese markets [14][17] Future Outlook - **Growth Expectations**: Anticipation of maintaining growth trends in the second half of the year, driven by AI technology applications and collaborations with leading multinational companies [5][6] - **Capacity Expansion**: Plans to increase capacity with new leased facilities to accommodate around 300 chemists by late 2025 or early 2026 [18] - **Investment in AI**: Ongoing investment in AI technology for drug discovery and project management, with plans to enhance capabilities further [26][27] Additional Insights - **Production Capacity Utilization**: Current capacity utilization is at industry average levels of 60%-70%, with ongoing assessments to meet increasing order demands [7][8] - **Cash Reserves**: Strong cash flow and improved accounts receivable turnover, maintaining a healthy cash reserve without significant pressure [25] - **Regulatory Environment**: Monitoring potential future drug tariffs that could impact the industry, with proactive global expansion strategies in place [22][23] This summary encapsulates the key points from the conference call, highlighting the financial performance, strategic initiatives, market conditions, and future outlook for Yaoshi Technology.

Group 1: Financial Performance - The company achieved a revenue of 920 million yuan in the first half of 2025, representing a year-on-year growth of 23.48% [2] - The net cash flow from operating activities was 467 million yuan, an increase of 240.62% compared to the same period last year [3] - The gross profit margin has shown a slight improvement of 1.4 percentage points from Q1 to Q2, indicating a stabilization trend [3] Group 2: Strategic Focus and Business Development - The company is focusing on three key strategies: concentrating on strategic clients, enhancing technological innovation, and expanding new business growth areas [2] - There has been a 19.88% year-on-year increase in new orders for CDMO business [3] - Revenue from multinational pharmaceutical companies (MNCs) increased by 69.73% year-on-year, reflecting deepening collaborations [3] Group 3: Operational Efficiency and Cost Management - The company is maintaining a capacity utilization rate of 60%-70% in mature workshops, which is considered a reasonable industry level [4] - Cost control measures are being strengthened to balance between cost management and strategic development [3] - The company has implemented various cost-reduction and efficiency-enhancing measures since the second half of last year [5] Group 4: Future Outlook and Market Trends - The company anticipates continued revenue growth in the second half of the year, supported by a favorable order backlog and market demand recovery [4] - There is a plan to expand fixed asset investments to meet the growing demand for new molecular drugs [6] - The company is confident in stabilizing and gradually returning the gross profit margin to an ideal level [5] Group 5: AI and Technological Integration - The company has systematically integrated AI applications across multiple business areas, generating over 80 million novel molecular blocks [10] - AI tools are being utilized to enhance operational efficiency, particularly in project reporting and document processing [10] - Future plans include expanding AI investments and deploying automated laboratory and robotic equipment [10]

Core Viewpoint - The company, Haoyuan Pharmaceutical, is enhancing the competitiveness of its wholly-owned subsidiary, Anhui Haoyuan, by implementing a capital increase through debt-to-equity conversion, amounting to 400 million yuan, to alleviate financial pressure and optimize its capital structure [1][4]. Group 1: Financial Performance - In Q1 2025, Haoyuan Pharmaceutical reported revenue of 606 million yuan, a year-on-year increase of 20.05%, and a net profit of 62.38 million yuan, up 272.28% [1][5]. - For the year 2024, the company achieved revenue of 2.27 billion yuan, a growth of 20.75%, and a net profit of 202 million yuan, reflecting a 58.17% increase [5][6]. - The R&D expenses for Q1 2025 were 53.71 million yuan, accounting for 8.86% of the revenue [1]. Group 2: Debt-to-Equity Conversion Details - The capital increase will raise Anhui Haoyuan's registered capital from 400 million yuan to 800 million yuan, maintaining its status as a wholly-owned subsidiary of Haoyuan Pharmaceutical [1][4]. - This is the second instance of debt-to-equity conversion for Anhui Haoyuan, following a previous increase of 200 million yuan in March 2024 [3][4]. Group 3: Business Operations and Market Position - Haoyuan Pharmaceutical focuses on providing efficient small molecule and new molecular type drugs for the global pharmaceutical and biopharmaceutical industries, continuously enhancing its market competitiveness through product pipeline expansion and technological iteration [1][5]. - The life science reagent business generated approximately 1.5 billion yuan in revenue in 2024, accounting for about 66% of total revenue, with a gross margin of 62.21% [6]. - The company has a total of 403 generic drug projects and 892 innovative drug projects, with many in the clinical trial stages, contributing to the global innovative drug development process [6].

Market Overview - In June 2025, the stock market experienced an overall rise due to the easing of Middle Eastern tensions and multiple thematic catalysts, while bond market interest rates declined [4][7] - The average parity of convertible bonds reached a near-high level, with significant valuation increases for bond-like convertible bonds [5][7] - The China Securities Convertible Bond Index closed at 442.1 points on June 27, marking a 2.68% increase for the month [7] Convertible Bond Market Analysis - As of June 27, the arithmetic average parity of convertible bonds was 103.14 yuan, up 3.77% from the previous month, placing it in the 98th percentile since 2023 [7][23] - The average conversion premium rate for bonds in the price range of 90 to 125 yuan was 21.13%, also in the 48th percentile for 2023 [7][23] - The average yield to maturity (YTM) for bond-like convertible bonds fell below zero, indicating a shift in market sentiment [7][29] Recommended Convertible Bonds - The "Top Ten Convertible Bonds" for July 2025 include: - **Shenzhen Gas Convertible Bond (113067.SH)**: High balance and stable profitability, rated AAA [31][32] - **Hongcheng Convertible Bond (110077.SH)**: Stable operations and high dividend payout, rated AA+ [31][43] - **Weir Convertible Bond (113616.SH)**: Strong growth in consumer electronics and automotive sectors, rated AA+ [31][55] - **Jingce Convertible Bond (123176.SZ)**: Urgent need for domestic semiconductor testing equipment, rated AA- [31][66] - **Haoyuan Convertible Bond (118051.SH)**: Recovery trend in innovative drug development, rated AA- [31][79] - **Huakang Convertible Bond (111018.SH)**: Leading position in functional sugar alcohols, rated AA- [31][90] - **Bohai Convertible Bond (113069.SH)**: Steady growth in special alloy materials, rated AA [31][101] - **Dongcai Convertible Bond (113064.SH)**: Increased demand for high-frequency resin materials driven by AI server construction, rated AA [31][113] Industry Insights - The gas industry, represented by Shenzhen Gas, is experiencing steady growth in natural gas sales, with a 5.06% year-on-year increase in supply volume [36] - The environmental governance sector, led by Hongcheng Environment, shows stable revenue growth from water supply and treatment services, with a focus on expanding its business footprint [46] - The semiconductor industry, highlighted by Weir Group, is benefiting from increased demand in automotive electronics and consumer electronics, with significant revenue growth projected [58] - The healthcare sector, represented by Haoyuan Pharmaceutical, is positioned to capitalize on the recovery of innovative drug research and development [82]

Core Viewpoint - Shanghai Haoyuan Pharmaceutical Co., Ltd. received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting a detailed response about its business operations and financial performance. Group 1: Main Business Operations - The company reported a total revenue of 2,253.67 million yuan from its research and experimental development sector in 2024, with a year-on-year growth of 32.41% in the front-end molecular building blocks and tool compounds business, generating 1,499.07 million yuan [1][4] - The product sales revenue in this segment was 1,363.90 million yuan, reflecting a 36.01% increase, while the gross profit margin stood at 63.74% [1][4] - The back-end raw materials and intermediates development business generated 754.61 million yuan, with a modest year-on-year growth of 2.49%, but product sales in this segment saw a decline of 30.45% [1][4] Group 2: Revenue and Profitability Analysis - Domestic and overseas business revenues were 1,391.69 million yuan and 861.99 million yuan respectively, with gross profit margins of 38.82% and 46.8% [1][4] - The company provided a detailed breakdown of its four business segments, including revenue, gross profit margins, and year-on-year changes, indicating a comprehensive analysis of market size and competitive landscape [1][4][6] Group 3: Market Trends and Growth Potential - The global pharmaceutical R&D expenditure is projected to grow at a rate of 4.2% annually, reaching 254 billion USD by 2026, which is expected to positively impact the life sciences reagent market [6][7] - The Chinese research reagent market has expanded from approximately 25 billion yuan in 2018 to about 48 billion yuan in 2022, with a compound annual growth rate of around 18% [6][7] - The global CDMO market is also on a growth trajectory, with expectations to reach 124.3 billion USD by 2025, indicating a robust demand for innovative drug development services [9][10] Group 4: Competitive Positioning - The company has established itself as a competitive player in the life sciences reagent sector, particularly in the molecular building blocks and tool compounds market, which is characterized by strong customization capabilities and a growing customer base [2][4] - The company’s tool compounds business is positioned favorably compared to peers, with higher revenue growth and gross profit margins, reflecting its strong international influence [11][12] - The company’s performance in the generic drug intermediates and raw materials sector aligns with industry trends, with a notable increase in the market for high-end pharmaceutical intermediates [13][14]

Summary of Bid Pharma Conference Call Company Overview - Bid Pharma is focused on the front end of new drug research and development, primarily dealing with molecular building blocks and scientific reagents [14][3] - The company was established in 2007 and is headquartered in Shanghai, with additional operational centers in Germany and India [14] Financial Projections - Expected revenue for 2025 is 2.18 billion yuan, representing a 21% year-over-year growth [2][3] - Projected profit for 2025 is 148 million yuan, with a 26% year-over-year increase [2][3] - Target market capitalization is 5.18 billion yuan, with a target stock price of 57 yuan, indicating approximately 30% upside potential from the current price of 41 yuan [2][3] Industry Insights - The molecular building block industry is experiencing continuous growth, with a projected global market size of 54.6 billion USD by 2026, accounting for about 25% of pharmaceutical R&D innovation costs [2][6] - The domestic market is seeing a shift towards local alternatives, with only 10% of the high-end scientific reagent market currently held by domestic companies [7] Business Strategy - Bid Pharma's overseas business has increased from approximately 40% in 2019 to 56% in 2024, with a goal of reaching 70% [2][9] - The gross margin for overseas business is significantly higher than domestic, which is a key reason for expanding international operations [9] - The company has a diverse customer base, including multinational pharmaceutical companies, domestic firms, CROs, research institutions, and universities, with 80% of sales made through direct sales [10][11] Competitive Advantages - Bid Pharma has a robust brand system and a diverse customer structure, which stabilizes revenue growth [10][11] - The company offers a wide range of products, with 130,000 types of stock available and the ability to provide 400,000 novel molecular building blocks [14][19] - The company is focusing on enhancing its R&D capabilities and expanding its product offerings to meet customer needs [19] Market Trends - The global pharmaceutical R&D investment is expected to reach 417.7 billion USD by 2030, with China accounting for approximately 76.6 billion USD [6] - The trend towards domestic alternatives in the scientific reagent market is becoming more pronounced due to increased domestic R&D investment and advantages in supply cycles and pricing [7] Future Outlook - The company anticipates a 20% growth in molecular reagents and a potentially faster growth rate of around 30% for scientific reagents over the next three years [12] - The overall gross margin is expected to improve as the proportion of high-margin overseas business increases [12][13] Shareholder Structure and Incentives - The controlling shareholders, Dai Lan and Dai Long, hold approximately 47% of the company’s shares [4][15] - A stock incentive plan was introduced in 2024, requiring revenue growth of no less than 10% and profit growth of no less than 20% for 2025 and 2026 [15] Investment Recommendations - Given the expected 35x P/E ratio for 2025, there is a near 30% upside potential, making it a favorable investment opportunity [21] - Investors are advised to consider low-entry opportunities, especially in the current market environment where high volatility exists [22]